THRD: Third Harmonic Bio Inc Price to Sales
The development of immune-based allergy medications is not subject to economic cycles or seasonality. The historical P/S ratio of Third Harmonic Bio on GURU.Markets reflects the dynamics of investor expectations, where represents the current level of the metric. The market is pricing in the safety of early molecule tests for Third Harmonic Bio, while the business relies on long-term demand for chronic inflammation therapies protected by patents.
Metric breakdowns and analytics for Third Harmonic Bio, Inc (THRD)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Third Harmonic Bio|THRD - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Third Harmonic Bio Inc|THRD - Company Aggregate Debts|Debt to Book Value Ratio Third Harmonic Bio, Inc|THRD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Third Harmonic Bio|Intermediate Coverage Ratio thirdharmonicbio.com
- earnings and market ratios statistics:
THRD - Net Profit|Projected Future Earnings Third Harmonic Bio|THRD - Price to Earnings Ratio|Future Price to Earnings Multiple Third Harmonic Bio Inc.|THRD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Third Harmonic Bio, Inc|THRD - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Third Harmonic Bio|THRD - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months thirdharmonicbio.com|THRD - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Third Harmonic Bio
- issuer revenue and sales details:
General company analysis:thirdharmonicbio.com (THRD)
The P/S ratio captures the relationship between market capitalization and annual operating revenue, allowing the real value of the business to be decoupled from speculative expectations. By analyzing the current P/S valuation, an investor can identify an overpayment for the asset, which is critical for Third Harmonic Bio (THRD) due to the lack of stable earnings and a dependence on the risky results of clinical trials for immunological drugs.
Who Third Harmonic Bio competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|Protagonist Corp - Market Cap to Sales Volume|IMVT: P/S Multiple|kiniksa.com - Market Capitalization-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Adaptive Biotech (ADPT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|VERA: Market Cap to Revenue Ratio|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL: P/S Multiple|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|P/S Multiple pharming.com|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM - Market Cap to Revenue|GOSS - Price-to-Revenue Ratio|Price to Sales kalvista.com|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PVLA|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|enGene - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RAPT|Aerovate - P/S Multiple|ACRS: Price-to-Revenue Ratio|KYTX: P/S Multiple|TLSA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Cabaletta Bio|Price to Sales Ventyx Biosciences Inc. VTYX|Market Cap to Revenue THTX (Theratechnologies Inc)|Market Cap to Sales Volume AVTX|P/S Multiple ELDN (Eledon Pharmaceuticals)|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ZURA (Zura Bio Ltd)|ATYR: P/S Multiple|Market Cap to Revenue Ratio ADAG|Price-to-Revenue Ratio ImageneBio|Shattuck Therapeutics - Price-to-Sales Ratio|P/S Multiple EQ|CNTB (connectbiopharm.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|adicetbio.com (ACET) - Price-to-Revenue Ratio|Market Cap to Revenue Celularity|INMB (INmune Bio Corp) - P/S Multiple|P/S Multiple Barinthus Biotherapeutics Corp|Market Cap to Revenue KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AKTX (Akari Therapeutics Plc)|Price-to-Revenue Coefficient Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Revenue Ratio|GeoVax Corp (GOVX) - Market Cap to Revenue|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|Market Cap to Revenue ibioinc.com|Market Cap to Revenue CARM|P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Revenue Ratio|P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Price to Sales|ADTX: Market Cap to Revenue|GRI Bio Inc - Market Cap to Sales Volume|XRTX: P/S Multiple|Vyome Therapeutics - Market Capitalization-to-Revenue Ratio|REVB (Revelation Biosciences) - P/S Multiple|indaptusrx.com (INDP) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI (calcimedica.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AFMD (Affimed N.V.)|ALLK: Market Cap to Revenue Ratio|HOOK: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IGMS (IGM Biosciences, Inc.)|ITOS: P/S Multiple|Ocean Biomedical Inc - Market Capitalization-to-Revenue Ratio|TCBP (TC BioPharm (Holdings) PLC) - P/S Multiple
